Integrated care pathways and the hub-and-spoke model for the management of non-melanoma skin cancer: A proposal of the Italian Association of Hospital Dermatologists (ADOI)

The term non-melanoma skin cancer (NMSC) refers to skin cancer different from melanoma, and it is usually restricted to basal cell carcinoma (BCC), squamous cell carcinoma (SCC) and their pre-cancerous lesions, e.g., actinic keratosis. These conditions represent the most frequent tumors in Caucasians and are characterized by an increasing incidence worldwide and a high socio-economic impact. The term Integrated Care Pathway (ICP) refers to “a complex intervention for the mutual decision making and organization of care processes for a well-defined group of patients during a well-defined period”. The purpose of this paper is to present a proposal from the Italian Association of Hospital Dermatologists (ADOI) for an ICP organization of care of NMSC, considering the hub-and-spoke model in the different geographical areas. This proposal is based on the most recent literature and on documents from the Italian Association of Medical Oncology (AIOM), the European consensus-based interdisciplinary guidelines from the European Association of Dermato- Oncology (EADO), and the National Comprehensive Cancer Network (NCCN). We initially discuss the NMSC outpatient clinic, the role of the multidisciplinary working groups, and the hub-and-spoke model regarding this topic. Then, we define the ICP processes specific for BCC and SCC. The ICP for NMSC is an innovative strategy to guarantee the highest possible quality of health care while the hub-andspoke model is crucial for the organization of different health care structures. Considering the importance on this topic, it is essential to create a valid ICP together with an efficient organization within the different geographical areas.

[1]  I. Zalaudek,et al.  Diagnosis and treatment of basal cell carcinoma: European consensus-based interdisciplinary guidelines. , 2019, European journal of cancer.

[2]  C. Schmults,et al.  Performance of the American Joint Committee on Cancer Staging Manual, 8th Edition vs the Brigham and Women's Hospital Tumor Classification System for Cutaneous Squamous Cell Carcinoma. , 2019, JAMA dermatology.

[3]  H. C. de Vijlder,et al.  Recurrence rates of cutaneous squamous cell carcinoma of the head and neck after Mohs micrographic surgery vs. standard excision: a retrospective cohort study , 2018, The British journal of dermatology.

[4]  E. Dellambra,et al.  Basal Cell Carcinoma: From Pathophysiology to Novel Therapeutic Approaches , 2020, Biomedicines.

[5]  J. Gehl,et al.  Updated standard operating procedures for electrochemotherapy of cutaneous tumours and skin metastases , 2018, Acta oncologica.

[6]  J. Schachter,et al.  Pembrolizumab Monotherapy for Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma: A Single-Arm Phase II Trial (KEYNOTE-629) , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  R. Dummer,et al.  Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): a multicentre, randomised, double-blind phase 2 trial. , 2015, The Lancet. Oncology.

[8]  R. Carroll,et al.  Mohs surgery is the treatment of choice for recurrent (previously treated) basal cell carcinoma. , 1989, The Journal of dermatologic surgery and oncology.

[9]  P. Steijlen,et al.  Photodynamic therapy versus topical imiquimod versus topical fluorouracil for treatment of superficial basal-cell carcinoma: a single blind, non-inferiority, randomised controlled trial. , 2013, The Lancet. Oncology.

[10]  R. Griffiths,et al.  Audit of clinical and histological prognostic factors in primary invasive squamous cell carcinoma of the skin: assessment in a minimum 5 year follow-up study after conventional excisional surgery. , 2002, British journal of plastic surgery.

[11]  S. Devarakonda Hub and spoke model: making rural healthcare in India affordable, available and accessible. , 2016, Rural and remote health.

[12]  J. Bernhard,et al.  Topical imiquimod or fluorouracil therapy for basal and squamous cell carcinoma: a systematic review. , 2009, Archives of dermatology.

[13]  Gregor Sersa,et al.  European Research on Electrochemotherapy in Head and Neck Cancer (EURECA) project: Results of the treatment of skin cancer. , 2016, European journal of cancer.

[14]  A. Hauschild,et al.  Sonidegib and vismodegib in the treatment of patients with locally advanced basal cell carcinoma: a joint expert opinion , 2020, Journal of the European Academy of Dermatology and Venereology : JEADV.

[15]  W. High,et al.  Intralesional agents in the management of cutaneous malignancy: a review. , 2011, Journal of the American Academy of Dermatology.

[16]  B. Schönfisch,et al.  Analysis of risk factors determining prognosis of cutaneous squamous-cell carcinoma: a prospective study. , 2008, The Lancet. Oncology.

[17]  L. Golitz,et al.  Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from two phase III, randomized, vehicle-controlled studies. , 2004, Journal of the American Academy of Dermatology.

[18]  O. Hansen,et al.  Platinum-based cytotoxic therapy in basal cell carcinoma--a review of the literature. , 1996, Acta oncologica.

[19]  E. Epstein,et al.  Basal cell carcinomas arise from hair follicle stem cells in Ptch1(+/-) mice. , 2011, Cancer cell.

[20]  M. Leader,et al.  Review of high‐risk features of cutaneous squamous cell carcinoma and discrepancies between the American Joint Committee on Cancer and NCCN Clinical Practice Guidelines In Oncology , 2017, Head & neck.

[21]  V. Gebski,et al.  Squamous cell carcinoma of the lip: is there a role for adjuvant radiotherapy in improving local control following incomplete or inadequate excision? , 2003, ANZ journal of surgery.

[22]  G. Goldenberg,et al.  Basal Cell Carcinoma: A Comprehensive Review of Existing and Emerging Nonsurgical Therapies. , 2016, The Journal of clinical and aesthetic dermatology.

[23]  A. Hauschild,et al.  Vismodegib in patients with advanced basal cell carcinoma: Primary analysis of STEVIE, an international, open-label trial. , 2017, European journal of cancer.

[24]  K. Gross,et al.  Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: a double-blind, randomized, vehicle-controlled study. , 2002, Journal of the American Academy of Dermatology.

[25]  J. Leonardi-Bee,et al.  Interventions for non-metastatic squamous cell carcinoma of the skin: systematic review and pooled analysis of observational studies , 2013, BMJ.

[26]  R. Dummer,et al.  Long‐term efficacy and safety of sonidegib in patients with locally advanced and metastatic basal cell carcinoma: 30‐month analysis of the randomized phase 2 BOLT study , 2017, Journal of the European Academy of Dermatology and Venereology : JEADV.

[27]  P. Broganelli,et al.  Usefulness of Photodynamic Therapy as a Possible Therapeutic Alternative in the Treatment of Basal Cell Carcinoma , 2015, International journal of molecular sciences.

[28]  S. Shumack,et al.  Efficacy of topical 5% imiquimod cream for the treatment of nodular basal cell carcinoma: comparison of dosing regimens. , 2002, Archives of dermatology.

[29]  Aleksandar Sekulic,et al.  Efficacy and safety of vismodegib in advanced basal-cell carcinoma. , 2012, The New England journal of medicine.

[30]  E. G. Kuflik Cryosurgery for Skin Cancer: 30‐Year Experience and Cure Rates , 2004, Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.].

[31]  C. Barker,et al.  Basal cell carcinoma: Contemporary approaches to diagnosis, treatment, and prevention. , 2019, Journal of the American Academy of Dermatology.

[32]  K. Peris,et al.  Update of the European guidelines for basal cell carcinoma management , 2014, European Journal of Dermatology.

[33]  I. Zalaudek,et al.  European interdisciplinary guideline on invasive squamous cell carcinoma of the skin: Part 1. epidemiology, diagnostics and prevention. , 2020, European journal of cancer.

[34]  A. Hauschild,et al.  PD‐1 Blockade with Cemiplimab in Advanced Cutaneous Squamous‐Cell Carcinoma , 2018, The New England journal of medicine.

[35]  S. Porceddu Prognostic factors and the role of adjuvant radiation therapy in non-melanoma skin cancer of the head and neck. , 2015, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

[36]  F. Lacarrubba,et al.  The use of imiquimod 5% cream for the treatment of basal cell carcinoma as observed in Gorlin's syndrome , 2003, Clinical and experimental dermatology.

[37]  M. Cristofolini,et al.  Epidemiology of Skin Tumors: Data from the Cutaneous Cancer Registry in Trentino, Italy , 2003, Journal of cutaneous medicine and surgery.

[38]  A. Hauschild,et al.  Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study , 2017, BMC Cancer.

[39]  D. Ekwueme,et al.  Years of Potential Life Lost and Indirect Costs of Melanoma and Non-Melanoma Skin Cancer , 2011, PharmacoEconomics.

[40]  D. Brodland,et al.  Surgical margins for excision of primary cutaneous squamous cell carcinoma. , 1992, Journal of the American Academy of Dermatology.

[41]  E. Dellambra,et al.  [The integrated care pathway for non melanoma skin cancer: the Istituto Dermopatico dell'Immacolata - IRCCS experience in Rome.] , 2020, Recenti progressi in medicina.

[42]  P. Steijlen,et al.  Three-Year Follow-Up Results of Photodynamic Therapy vs. Imiquimod vs. Fluorouracil for Treatment of Superficial Basal Cell Carcinoma: A Single-Blind, Noninferiority, Randomized Controlled Trial. , 2016, The Journal of investigative dermatology.

[43]  P. Ascierto,et al.  Electrochemotherapy efficacy evaluation for treatment of locally advanced stage III cutaneous squamous cell carcinoma: a 22-cases retrospective analysis , 2017, Journal of Translational Medicine.

[44]  A. Testori,et al.  Electrochemotherapy for cutaneous and subcutaneous tumor lesions: a novel therapeutic approach , 2010, Dermatologic therapy.

[45]  Roma H. Patel,et al.  Immune Checkpoint Inhibitors for Treating Advanced Cutaneous Squamous Cell Carcinoma , 2019, American Journal of Clinical Dermatology.

[46]  A. Hauschild,et al.  Phase 2 study of cemiplimab in patients with metastatic cutaneous squamous cell carcinoma: primary analysis of fixed-dosing, long-term outcome of weight-based dosing , 2020, Journal for immunotherapy of cancer.

[47]  A. Guminski,et al.  Immunotherapy and other systemic therapies for cutaneous SCC. , 2019, Oral oncology.

[48]  J. Fortenberry,et al.  The hub-and-spoke organization design: an avenue for serving patients well , 2017, BMC Health Services Research.

[49]  J. Hercogová,et al.  Superpulsed CO2 Laser Treatment of Basal Cell Carcinoma With Intraoperatory Histopathologic and Cytologic Examination , 2002, Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.].

[50]  E. Dennett,et al.  The incidence of metastasis from cutaneous squamous cell carcinoma and the impact of its risk factors , 2012, Journal of surgical oncology.

[51]  A. Sidoroff,et al.  European Dermatology Forum guidelines on topical photodynamic therapy , 2015, European Journal of Dermatology.

[52]  E. Dellambra,et al.  Cutaneous Squamous Cell Carcinoma: From Pathophysiology to Novel Therapeutic Approaches , 2021, Biomedicines.

[53]  L. Buchmann,et al.  Elective Neck Dissection for Head and Neck Cutaneous Squamous Cell Carcinoma with Skull Base Invasion , 2017, Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery.

[54]  D. Leffell,et al.  Management of nonmelanoma skin cancer in 2007 , 2007, Nature Clinical Practice Oncology.

[55]  S. Mocellin,et al.  Basal cell carcinoma: 10-year experience with electrochemotherapy , 2017, Journal of Translational Medicine.

[56]  Konstantin Moskalik,et al.  The efficacy of facial skin cancer treatment with high-energy pulsed neodymium and Nd:YAG lasers. , 2009, Photomedicine and laser surgery.

[57]  A. Hauschild,et al.  Cemiplimab in locally advanced basal cell carcinoma after hedgehog inhibitor therapy: an open-label, multi-centre, single-arm, phase 2 trial. , 2021, The Lancet. Oncology.

[58]  Ivan Buzurovic,et al.  Definitive and Postoperative Radiation Therapy for Basal and Squamous Cell Cancers of the Skin: Executive Summary of an American Society for Radiation Oncology Clinical Practice Guideline. , 2019, Practical radiation oncology.

[59]  C. Berking,et al.  Cemiplimab in locally advanced cutaneous squamous cell carcinoma: results from an open-label, phase 2, single-arm trial. , 2020, The Lancet. Oncology.

[60]  Q. Kan,et al.  Comparison between wait-and-see policy and elective neck dissection in clinically N0 cutaneous squamous cell carcinoma of head and neck , 2018, Medicine.

[61]  R. Schwartz,et al.  Topical pharmacotherapy for skin cancer: part I. Pharmacology. , 2014, Journal of the American Academy of Dermatology.

[62]  H. Williams,et al.  Interventions for basal cell carcinoma of the skin: systematic review , 2004, BMJ : British Medical Journal.

[63]  M. W. M. Jaspers,et al.  Two Decades of Teledermatology: Current Status and Integration in National Healthcare Systems , 2016, Current Dermatology Reports.